Molecular Partners AG presented new preclinical data on its Radio‑DARPin platform at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai, China, on March 19–20 2026.
The presentation highlighted the platform’s isotope‑agnostic design, showing that two Radio‑DARPin candidates targeting distinct tumor antigens had comparable biodistribution when labeled with Lutetium‑177 or Lead‑203. The similar uptake and washout rates support the platform’s ability to interchange therapeutic isotopes without compromising target engagement.
The data reinforce the company’s lead DLL3‑targeted candidate MP0712, which is currently in a Phase 1/2a trial in the United States. The presentation also underscored the recent development agreement with Eckert & Ziegler, which will enable large‑scale production of Radio‑DARPin therapeutics, including candidates labeled with Actinium‑225 and Lutetium‑177. The isotope flexibility positions the platform to adapt to regulatory and supply constraints and to tailor treatments to patient needs.
Molecular Partners reported a net loss of CHF 61.7 million for the full year 2025, compared with a net loss of CHF 54.0 million in 2024, and no revenue for the year. Operating expenses were CHF 58.1 million, and the company held CHF 93.1 million in cash and cash equivalents as of December 31 2025, a runway that is expected to support operations through 2028.
CEO Patrick Amstutz said the platform’s isotope interchangeability “offers us the opportunity and flexibility to evaluate Radio‑DARPin candidates in an isotope‑agnostic manner and to choose the most suitable therapeutic isotope, as late as with initial clinical data, without having to restart the entire drug discovery and development process.” The presentation signals continued progress toward clinical translation and strengthens the company’s competitive positioning in the radiopharmaceutical space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.